Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
← catalyst calendarNCT06276491 · readout ≤ 499 d
Sponsored by Xencor, Inc. (industry) · XNCR — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
282estimated
Sites
18
Countries
Denmark, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-04 | actual | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Ovarian Cancer
- Endometrial Cancer
- Germ Cell Tumor
- Testicular Germ Cell Tumor
- Ovarian Germ Cell Tumor
Intervention
- Biological: XmAb541
Primary outcomes
what the primary-completion date above is the date OFIncidence of adverse events
measured Day 1 to 2 years
Incidence of dose-limiting toxicities (DLTs)
measured Day 1 to Day 28
Incidence of cytokine release syndrome (CRS)
measured Day 1 to Day 28
Permalink · XNCR's whole pipeline · Catalyst calendar · Every registered study · What changed